Last reviewed · How we verify
NCT07289087: QOL-ONE PRO-CT
Patient-Reported Outcomes in Allogeneic Stem Cell Transplantation and CAR-T Therapy
trial in Quality of Life in 162 participants. Not yet recruiting.
1 March 2027
Quick facts
| Lead sponsor | Associazione Qol-one |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 162 |
| Start date | 15 February 2026 |
| Primary completion | 1 March 2027 |
| Estimated completion | 1 April 2027 |
Conditions studied
- Quality of Life — all drugs for Quality of Life →
- Patient Reported Outcome (PRO) — all drugs for Patient Reported Outcome (PRO) →
- Allogeneic Blood and Marrow Transplantation (BMT) — all drugs for Allogeneic Blood and Marrow Transplantation (BMT) →
- CAR T Cell Therapy — all drugs for CAR T Cell Therapy →
Sponsor
Associazione Qol-one — full company profile →
Who can join
18 and older, any sex, with Quality of Life or Patient Reported Outcome (PRO). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
3.1. Overview Prospective, multicenter, observational cohort study comparing short-term PROs measured with the HM-PRO between two exposure groups: patients undergoing allogeneic stem cell transplantation (allo-SCT) and patients receiving CAR-T cell therapy. Patients will be enrolled at hospital admission for the index inpatient procedure and followed through the inpatient stay (admission → discharge). The study is non-randomized and designed to describe trajectories of symptoms and HRQoL and to estimate the between-group difference in deterioration of HM-PRO scores (primary estimand: mean difference in change score, CAR-T vs allo-SCT).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07289087
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Quality of Life
Currently open trials in the same condition.
- NCT07498959 — Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer · NA · recruiting
- NCT07416448 — Neuroma-Associated Pain Management After Combat-Related Trauma in Ukraine · NA · recruiting
- NCT07412379 — Predictive Factors for Functional and Quality of Life Decline in Patients >65 Years With a Gastrointestinal Tract Cancer · recruiting
- NCT07380789 — Comprehensive Multicenter Study on the Management of Acute Pain Following Thoracic Combat-Related Trauma in Ukraine · NA · recruiting
- NCT07280416 — Evolution of Insomnia During the First Year in Patients Newly Diagnosed With Cancer · recruiting
Other Associazione Qol-one trials
Trials by the same sponsor.
- NCT05924100 — Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant t · Phase 2 · recruiting
- NCT05188326 — Efficacy of 5-Aza for Post-Remission Therapy of Acute Myeloid Leukemia (AML) in Elderly Patients · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07289087 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Associazione Qol-one
- Last refreshed: 17 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07289087.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing